CRISPR Therapeutics (CRSP) News Today $47.91 -2.52 (-5.00%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$47.75 -0.16 (-0.33%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Cantor Fitzgerald Has Weak Estimate for CRSP FY2025 EarningsFebruary 23 at 2:01 AM | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Shares Down 4.1% - What's Next?CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 4.1% - What's Next?February 22 at 1:14 PM | marketbeat.comSamarth Kulkarni Sells 18,360 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) StockFebruary 22 at 6:38 AM | insidertrades.comFY2025 EPS Estimate for CRISPR Therapeutics Cut by AnalystCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for CRISPR Therapeutics in a research note issued to investors on Wednesday, February 19th. Cantor Fitzgerald analyst E. Schmidt now expects that the companFebruary 22 at 2:57 AM | marketbeat.comCRISPR Therapeutics AG (CRSP): Among the Most Oversold Healthcare Stocks to Buy NowFebruary 21 at 11:46 PM | msn.comCRISPR Therapeutics (NASDAQ:CRSP) Shares Up 3.4% - Here's WhyCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 3.4% - Here's WhyFebruary 21 at 7:07 PM | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 18,360 SharesCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the sale, the chief executive officer now owns 171,613 shares of the company's stock, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.February 21 at 5:56 PM | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 2% - What's Next?CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 2% - Should You Sell?February 21 at 2:55 PM | marketbeat.comCantor Fitzgerald Has Weak Outlook for CRSP FY2025 EarningsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for CRISPR Therapeutics in a report released on Wednesday, February 19th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will poFebruary 21 at 8:48 AM | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Stake Lifted by Allworth Financial LPAllworth Financial LP lifted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 2,117.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 15,078 shares of the company's stock after purchasing an additionalFebruary 21 at 3:33 AM | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Shares Gap Up - Time to Buy?CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap Up - What's Next?February 20 at 6:59 PM | marketbeat.comMarket Whales and Their Recent Bets on CRSP OptionsFebruary 20 at 4:42 PM | benzinga.comCRISPR set to snap six days of gains as shares trade in redFebruary 20 at 4:42 PM | msn.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 4.1% - Time to Sell?CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 4.1% - Should You Sell?February 20 at 1:42 PM | marketbeat.comVan ECK Associates Corp Boosts Position in CRISPR Therapeutics AG (NASDAQ:CRSP)Van ECK Associates Corp raised its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 5,269.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 83,010 shares of the company's stock after purchasing an addiFebruary 20 at 3:16 AM | marketbeat.comCitigroup Has Lowered Expectations for CRISPR Therapeutics (NASDAQ:CRSP) Stock PriceFebruary 20 at 2:34 AM | americanbankingnews.comCRISPR Therapeutics Sees Unusually High Options Volume (NASDAQ:CRSP)February 20 at 1:40 AM | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 3.4% - Here's What HappenedCRISPR Therapeutics (NASDAQ:CRSP) Shares Up 3.4% - Here's What HappenedFebruary 19, 2025 | marketbeat.comCantor Fitzgerald Reiterates "Neutral" Rating for CRISPR Therapeutics (NASDAQ:CRSP)Cantor Fitzgerald reissued a "neutral" rating on shares of CRISPR Therapeutics in a research note on Wednesday.February 19, 2025 | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Receives $74.50 Consensus Target Price from AnalystsFebruary 19, 2025 | americanbankingnews.comBrokerages Set CRISPR Therapeutics AG (NASDAQ:CRSP) Target Price at $74.50Shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) have received an average recommendation of "Moderate Buy" from the twenty-two brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, nine have assigned a hold ratingFebruary 19, 2025 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Shares Gap Up - Here's WhyCRISPR Therapeutics (NASDAQ:CRSP) Shares Gap Up - Time to Buy?February 18, 2025 | marketbeat.comCRISPR Therapeutics Target of Unusually Large Options Trading (NASDAQ:CRSP)CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) was the target of some unusual options trading activity on Tuesday. Investors purchased 13,128 call options on the stock. This is an increase of approximately 59% compared to the average volume of 8,282 call options.February 18, 2025 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Given New $82.00 Price Target at CitigroupCitigroup dropped their price target on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating on the stock in a research note on Tuesday.February 18, 2025 | marketbeat.comCiti Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP)February 18, 2025 | markets.businessinsider.comCrispr Therapeutics price target lowered to $82 from $89 at CitiFebruary 18, 2025 | markets.businessinsider.comCRISPR Therapeutics (CRSP) Expected to Announce Quarterly Earnings on WednesdayCRISPR Therapeutics (NASDAQ:CRSP) will be releasing earnings before the market opens on Wednesday, February 19, Financial Modeling Prep reports.February 17, 2025 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $32.00February 17, 2025 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Rating Upgraded by StockNews.comFebruary 16, 2025 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Earns "Market Outperform" Rating from JMP SecuritiesFebruary 16, 2025 | americanbankingnews.comBrookline Capital Management Weighs in on CRSP Q1 EarningsFebruary 16, 2025 | americanbankingnews.comCRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Moderate Buy" from AnalystsCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has earned an average rating of "Moderate Buy" from the twenty-two analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve haveFebruary 16, 2025 | marketbeat.comThe Goldman Sachs Group Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $57.00February 16, 2025 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Sees Large Volume Increase After Analyst UpgradeFebruary 16, 2025 | americanbankingnews.comCrispr Therapeutics upgraded to Outperform from In Line at Evercore ISIFebruary 15, 2025 | markets.businessinsider.comResearch Analysts Set Expectations for CRSP FY2025 EarningsFebruary 15, 2025 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $32.00 at Morgan StanleyMorgan Stanley increased their price target on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an "underweight" rating in a research report on Friday.February 15, 2025 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Rating Upgraded by Evercore ISIEvercore ISI upgraded CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and increased their price target for the company from $60.00 to $99.00 in a research note on Friday.February 15, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for CRISPR Therapeutics (NASDAQ:CRSP)February 15, 2025 | americanbankingnews.comCRISPR Therapeutics' (CRSP) "Buy" Rating Reaffirmed at Needham & Company LLCFebruary 15, 2025 | americanbankingnews.comResearch Analysts Offer Predictions for CRSP Q1 EarningsFebruary 15, 2025 | americanbankingnews.comWhy CRISPR Therapeutics (CRSP) Soared on Friday?February 15, 2025 | finance.yahoo.comWilliam Blair Issues Negative Forecast for CRSP EarningsFebruary 15, 2025 | americanbankingnews.comCRISPR Therapeutics upgraded to Outperform by Evercore ISIFebruary 14, 2025 | ca.finance.yahoo.comCRISPR Therapeutics upgraded to Outperform by Evercore ISIFebruary 14, 2025 | ca.finance.yahoo.comCrispr Therapeutics AG (CRSP) Gets a Sell from Morgan StanleyFebruary 14, 2025 | markets.businessinsider.comCrispr Therapeutics AG (CRSP) Gets a Sell from Morgan StanleyFebruary 14, 2025 | markets.businessinsider.comCRISPR upped to outperform by Evercore on upcoming dataFebruary 14, 2025 | seekingalpha.comCRISPR upped to outperform by Evercore on upcoming dataFebruary 14, 2025 | seekingalpha.comCRISPR Therapeutics stock rises following analyst upgradeFebruary 14, 2025 | msn.com Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address CRSP Media Mentions By Week CRSP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRSP News Sentiment▼0.350.60▲Average Medical News Sentiment CRSP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRSP Articles This Week▼4212▲CRSP Articles Average Week Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Moderna News Neurocrine Biosciences News Bio-Techne News Vaxcyte News Exelixis News Qiagen News Repligen News Halozyme Therapeutics News Revolution Medicines News Krystal Biotech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRSP) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
